Sign In

Original late-breaking scientific research conducted and submitted after the original abstract deadline of June 1, 2017 were be reviewed for presentation at The Liver Meeting®. Accepted late-breaking abstracts are listed below.

Poster Sessions

Monday, October 23, 8 am-5:30 pm

  • LB-11:Safety, tolerability, and anti-fibrotic effect of PRI-724, a CBP/?-catenin inhibitor, in patients with hepatitis C virus cirrhosis: A single-center, open-label, dose escalation phase 1 trial
  • LB-12:HIV-1/HCV Coinfection Treatment with Single-Tablet Antiviral Regimens (CoSTARs): 12 Weeks of Ledipasvir/Sofosbuvir (LDV/SOF) after Randomized Switch to Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Rilpivirine/F/TAF (R/F/TAF)
  • LB-13:A Phase 1a Study of AT-527, a Novel Pan-Genotypic Purine Nucleotide Prodrug Inhibitor of Hepatitis C Virus (HCV)
  • LB-15:Safety, Tolerability, Pharmacokinetics and Antiviral Activity of JNJ-56136379, a Novel HBV Capsid Assembly Modulator, in Non-cirrhotic, Treatment-naïve Subjects with Chronic Hepatitis B.
  • LB-16:Real-world effectiveness and safety of Daclatasvir/Sofosbuvir with or without Ribavirin among genotype 5 and 6 Hepatitis C Virus patients
  • LB-17:Bi-weekly dosing of ARB-1467 LNP siRNA in HBeAg negative, virally suppressed patients with chronic HBV infection leads to deeper declines in HBsAg and potential association with IL28b
  • LB-18:No Evidence of 1-Year Reinfection after Treating HCV at a Methadone Program
  • LB-19:Liver Damage in Lipodystrophy and Impact of Metreleptin: Experience from a Large Retrospective Review
  • LB-20:The Safety and Efficacy of Sofosbuvir & Daclatasvir Combined Therapy for Treatment of Egyptian Children and Adolescents with Chronic Hepatitis C (HCV)-Genotype 4: Interim Results
  • LB-21:Subcutaneous delivery of a RNA interference (RNAi) therapeutic candidate for alpha-1 antitrypsin deficiency (AATD)-related liver disease produces deep and prolonged knockdown of plasma AAT.
  • LB-22:AIC649 in Combination with Entecavir Leads to WHsAg Loss in the Woodchuck Animal Model of Chronic Hepatitis B
  • LB-23:NASH screening with a fast diagnostic tool using mid infrared spectroscopy: a bi-centric study
  • LB-24:Interim follow-up analysis in the REP 401 protocol: functional control of HBeAg negative chronic HBV infection persists after withdrawal of combined therapy with REP 2139 or REP 2165, tenofovir disoproxil fumarate and pegylated interferon ?-2a
  • LB-25:Novel anti-viral activity of SB 9200, a RIGI agonist; results from Cohort 1 of the ACHIEVE trial
  • LB-26:Polymorphisms in the genotype 3 hepatitis C virus polymerase protein modify the response to interferon and sofosbuvir.
  • LB-27:Survival Benefit of Direct Acting Antiviral Therapy in Patients with Decompensated Cirrhosis
  • LB-28:First prospective evidence of decreased mortality after Direct acting antivirals in the French ANRS CO22 HEPATHER cohort
  • LB-29:Every-two-week ropeginterferon alfa-2b is safe with better efficacy in interferon naïve patients with chronic hepatitis B virus infection: A phase 2, open-label, randomized, active control, dose finding study

Late-Breaking Sessions

Monday, October 23, 3-4:30 pm

  • LB-1:Lusutrombopag for Treatment of Thrombocytopenia in Patients with Chronic Liver Disease Who Are Undergoing Non-Emergency Invasive Procedures: Results from An International Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (L-PLUS 2)
  • LB-2:The AESOP Trial: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Obeticholic Acid in Patients with Primary Sclerosing Cholangitis
  • LB-3:A long-term phase 2 safety and efficacy study of the apical sodium-dependent bile acid transporter inhibitor maralixibat in children with Alagille syndrome: preliminary results from the IMAGINE study
  • LB-4:Treatment efficacy and safety of low dose Seladelpar, a selective PPAR- ? agonist, in patients with primary biliary cholangitis: twelve-week interim analysis of an international, randomized, dose ranging, phase 2 study
  • LB-5:High Efficacy and Safety of the combination HCV Regimen Grazoprevir and Elbasvir for 8 Weeks in Treatment-Naive, non-severe fibrosis HCV GT1b-Infected Patients: Interim Results of the STREAGER study.
  • LB-6:Identification of PKD1L1 Gene Variants in Biliary Atresia Patients with Structural Malformations (BASM)

Tuesday, October 24, 8-9 am

  • LB-7:Everolimus allows a significant and safe reduction of tacrolimus exposure in the de novo liver transplantation recipients and improves kidney function: 52 weeks data from REDUCE study
  • LB-8:Topical imiquimod before intradermal hepatitis B vaccination in patients on dialysis
  • LB-9:Acetyl-CoA carboxylase (ACC) inhibitor GS-0976 leads to significant improvements in MRI-PDFF in a phase 2, randomized, placebo-controlled trial of patients with NASH
  • LB-10:A Biomarker Predictive of the Development of Portal Hypertension in Children with Alpha-1-AT Deficiency